Publication | Closed Access

Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial

Hematological MalignancyMedicineFirst-line Dadi TrialChronic Myeloid LeukaemiaHematologyClinical TrialsMyeloid NeoplasiaTreatment-free RemissionOncologyRadiation OncologyCancer ResearchHealth Sciences